Novartis Receives European Commission Approval For Itvisma® Gene Therapy For Spinal Muscular Atrophy

Itvisma Is A One-Time Fixed-Dose Gene Therapy For SMA Gene Replacement Therapies Now Eligible Across All Age Groups In The EU STEER And STRENGTH Studies Show Clinically Meaningful Benefit For SMA Patients Itvisma Becomes First Gene Replacement Therapy Approved For Broad SMA Population In The EU